Local Drug Delivery for Coronary Artery Disease: Established and Emerging Applications

Book Cover......Page 1
Title......Page 2
Copyright......Page 3
Contents......Page 4
List of contributors......Page 10
Preface......Page 24
1. The purpose of site-specific therapy......Page 25
2. Local drug delivery: impact of pressure, substance characteristics, and stenting on drug transfer into the arterial wall......Page 31
3. Catheter-based and stent-based treatment for coronary artery disease......Page 34
4. The ClearWay™ microporous balloon catheter......Page 52
5. The Dispatch® coronary infusion catheter......Page 62
6. The Remedy™ PTCA dilatation infusion cather......Page 71
7. The Infiltrator™ angioplasty balloon cather......Page 79
8. The Infiltrator™ local drug delivery cather......Page 86
9. The needle catheter......Page 90
10. Stent-mediated local drug delivery......Page 107
11. Silicon carbide-coated stents......Page 124
12. The Carbostent: a Carbofilm™-coatedstent......Page 133
13. The PC-coated BiodivYsio™ stent......Page 142
14. PTFE-covered stents......Page 150
15. Overview of drug delivery coatings......Page 158
16. Phosphorylcholine (PC Technology™) coated stents as a drug delivery platform......Page 174
17. Direct stent coating: an alternative for polymers?......Page 188
18. Radioactive stents......Page 202
19. Overview of potential drugs to inhibit in-stent restenosis......Page 212
20. Direct antithrombins......Page 214
21. Tissue factor inhibitors......Page 219
22. Nitric oxide-related interventions and restenosis......Page 223
23. Vitamin E and its multiple properties: anti, pro, and non-oxidative activities......Page 242
24. The dexamethasone eluting stent......Page 256
25. Antiinflammatory approaches to restenosis......Page 263
26. The role of matrix metalloproteinase inhibitors after arterial injury......Page 279
27. Methotrexate: a potential drug for stent-mediated local drug delivery: antiinflammatory and antiproliferative characteristics......Page 290
28. Actin-skeleton inhibitors: potential candidates for local drug delivery in the prevention of in-stent restenosis?......Page 301
29. Local delivery of antisense oligomers to c-myc for the prevention of restenosis......Page 319
30. Site-specific delivery of cytostatic agents......Page 330
31. Catheter-based delivery of NOS gene......Page 336
32. Carbon-coated stents: diamond-like stent coatings......Page 345
33. Long-term biocompatibility evaluation of poly-bis-trifluorethoxyphosphazene (PTFEP): a novel biodegradable polymer stent coating in a porcine coronary stent model......Page 354
34. Biocompatibility evaluation of biosoluble stent coatings in a porcine coronary stent model......Page 366
35. Glycoprotein (GP) GIIb/IIIa receptor antagonist eluting stents......Page 373
36. Activated protein C eluting stents......Page 378
37. Local methylprednisolone delivery using a BiodivYsio phosphorylcholine (PC)-coated drug delivery stents reduces inflammation and neointimal hyperplasia in a porcine coronary stent model......Page 380
38. Methotrexate loaded BOBSC-coated coronary stents reduce neointimal hyperplasia in a porcine coronary model......Page 390
39. Rapamycin eluting stents......Page 405
40. Preclinical evaluation of tacrolimus-coated coronary stents......Page 412
41. Local delivery of paclitaxel as a stent coating......Page 426
42. Addition of cytochalasin D to a biodegradable oil stent coating inhibits intimal hyperplasia in a porcine coronary model......Page 435
43. Vascular endothelial growth factor (VEGF) eluting stents......Page 452
44. An advanced antisense for local and stent based delivery for prevention of restenosis......Page 457
45. Stent-based gene delivery......Page 471
46. Catheter-based local heparin delivery......Page 476
47. Local delivery of low molecular weight heparins......Page 486
48. Local delivery of steroids before coronary stent implantation......Page 493
49. Clinical studies with the Carbostent......Page 511
50. Gold-coated stents......Page 518
51. Heparin-coated stent trials......Page 521
52. The Blue Medical 50% TEMPO coronary stent: preclinical studies and the first clinical pilot trial......Page 530
53. Dexamethasone: mode of action, preclinical, and clinical studies......Page 547
54. 17β-Estradiol-eluting stents: a potential therapy in the prevention of restenosis......Page 563
55. Batimastat: mode of action, preclinical, and clinical studies......Page 578
56. The FIM trial: sirolimus eluting stents......Page 596
57. Tacrolimus eluting stents......Page 602
58. Everolimus eluting stents......Page 607
59. The Quanam drug eluting stent and the SCORE trial......Page 616
60. The Boston Scientific paclitaxel eluting stent: TAXUS I and II......Page 626
61. Clinical results with non-polymer based taxol eluting stents. The European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial......Page 639
62. Intrapericardial drug delivery for prevention of restenosis......Page 654
63. Alternatives to drug eluting stents: safety and efficacy of systemic delivery of antiproliferative therapy to reduce in-stent neointimal hyperplasia......Page 667
64. Drug eluting stents: a critical perspective*......Page 683
Index......Page 695